Pheon Therapeutics Ltd. has completed a $120 million series B financing to fund the development of its pipeline of differentiated antibody-drug conjugates (ADCs) for cancer through clinical proof of concept.
Even though HER3 is validated as a promising therapeutic target for cancer therapy, no HER3-targeting antibodies or antibody-drug conjugates (ADCs) have been approved for clinical use. Investigators at Duality Biologics (Suzhou) Co. Ltd. have developed DB-1310, a new HER3-targeting ADC being studied for the treatment of solid tumors, and published findings from preclinical characterization.
Macrogenics Inc. CEO Scott Koenig said his firm is “on the right pathway” with vobramitamab duocarmazine (vobra duo), previously known as MGC-018, in metastatic castration-resistant prostate cancer. Wall Street proved less than thrilled, and shares of the Rockville, Md.-based firm (NASDAQ:MGNX) closed May 10 at $3.31, down $11.36, or 77%, after Macrogenics disclosed phase II results from the Tamarack study with vobra duo.
Researchers from Sichuan Baili Pharmaceutical Co. Ltd. and Systimmune Inc. presented preclinical data for the novel CD33-targeting antibody-drug conjugate (ADC) being evaluated for the treatment of hematologic malignancies.
Bioatla Inc. has received FDA clearance of its IND application for BA-3361, a conditionally active biologic (CAB)-Nectin-4 antibody-drug conjugate (ADC) for the treatment of multiple tumor types.
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that has gained the backing of an impressive group of investors in a recently closed $100 million series A round.
“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that has gained the backing of an impressive group of investors in a recently closed $100 million series A round.
Ten days early, the U.S. FDA granted full approval under priority review to Pfizer Inc. and Genmab A/S’s antibody-drug conjugate Tivdak (tisotumab vedotin) to treat cervical cancer.
Antibody-drug conjugates are the hot spot for deals in Asia, but investors questioned whether oncology is really the place to be, during the Asia Bio Partnering Forum in Singapore April 24 to 25.
RSS
